The company is partnering with leading ophthalmology practices focused on improving patient outcomes. OMNY solutions are derived from electronic health record data and provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes.
OMNY Health this week announced it has partnered with the nation's leading community-based ophthalmology practices to launch a real-world data ecosystem focused on driving collaborative research partnerships to advance treatments and improve outcomes in patients with ophthalmic disorders.
According to a news release, OMNY solutions are derived from electronic health record data and provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes. De-identified images from retinal scans and other images also are available from ecosystem partners, allowing researchers to view physical changes in condition severity over time.
A diverse set of providers are participating in the ecosystem, from large independent ophthalmology group practices to academic medical centers, integrated delivery networks, specialty hospitals, and regional health systems. Practices participating in the OMNY ecosystem will leverage OMNY's platform to opt into clinical trials, prospective observational surveys, and other collaborative research opportunities.
Mitesh Rao, MD, CEO, OMNY Health, said in a news release that the company is pleased to welcome its new ophthalmology providers to the network.
“Over the past year, we have made great strides connecting researchers and providers in the dermatology space and are looking forward to making the same level of impact on ophthalmology," Rao said in the news release.
"US Eye looks forward to continuing to strengthen our partnership with OMNY Health and find new ways to leverage our data internally," said Kinga Huse, president, US Eye. "The ability to make more data-driven decisions that improve outcomes and the patient experience will be a valuable asset for our providers and patients."
According to Amy Goodson-Burke, chief revenue officer for American Vision Partners, the company was pleased that OMN elected to prioritize ophthalmology.
“As a data driven organization, we view this partnership as a conduit to leverage our data to gain new insights in providing care for our patients,” she said in the news release. “The added visibility into additional clinical research opportunities will allow our providers to continue their focus on finding new ways to care for and treat our patients in their efforts to preserve sight.”
Jonathan Lujan, CEO, Sight Growth Partners, noted that as an administrative services provider for ophthalmology practices, his company’s primary focus is to listen to our doctors and provide support for them so they can care for their patients in a better way.
“We are partnering with OMNY Health to do exactly that … exceed our physician's needs so they can exceed their patient's needs," Lujan said in a statement.
David Shoemaker, MD, founder and CEO, US Eye, lauded the effort.
“It will allow us to better understand our patient populations, obtain more insight into the impact of care patterns on outcomes, and better align clinical trial opportunities with specific patient cohorts," he said in the news release.
With an uptick in ophthalmology drug research and approvals in the past few years, researchers can utilize this data to expedite clinical trial recruitment and design, understand evolving treatment patterns, assess trends in healthcare resource utilization, understand current gaps in care, conduct comparative effectiveness studies, and partner with ophthalmology practices around joint missions focused on quality improvement and patient outcomes.
Key populations available in the dataset include dry eye (296K patients), dry age-related macular degeneration (AMD) (109K patients), wet AMD (31K patients), and diabetic retinopathy (64K patients). This unique data asset also includes populations with rare eye diseases such as Stargardt Disease and pediatric populations with congenital disease.
Like other OMNY Health specialty-focused databases, the ophthalmology data set also includes information on pharmacy orders, lab results, medical device detail for implants, and detailed provider clinical assessment measures such as best corrected visual acuity and intraocular pressure values. OMNY will be conducting ophthalmology solution demonstrations and presenting results from studies during a variety of events this summer, including ISPOR, DIA, and ICPE.